美迪西(688202.SH):美熹企業等3名股東擬合計減持不超0.93%股份
格隆匯6月25日丨美迪西(688202.SH)公佈,股東美斕企業、美劭企業和美熹企業擬通過集中競價或大宗交易方式合計減持公司股票不超過57.8452萬股,即不超過公司總股本的0.93%。其中,競價交易減持期間為2021年7月19日至2022年1月18日,大宗交易減持區間為2021年7月1日至2021年12月31日,減持價格按市場價格確定。
美斕企業、美劭企業、美熹企業均為由上海澤嫻投資管理有限公司擔任普通合夥人的合夥企業,三者構成一致行動關係,合計持有190.5912萬股,佔公司總股本的3.07%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.